Northern Trust Corp trimmed its stake in shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) by 2.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,128,641 shares of the biopharmaceutical company’s stock after selling 25,697 shares during the period. Northern Trust Corp’s holdings in Catalyst Pharmaceuticals were worth $2,167,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. MetLife Investment Advisors LLC grew its stake in Catalyst Pharmaceuticals by 38.1% during the third quarter. MetLife Investment Advisors LLC now owns 69,540 shares of the biopharmaceutical company’s stock valued at $263,000 after acquiring an additional 19,191 shares in the last quarter. Meeder Asset Management Inc. grew its stake in Catalyst Pharmaceuticals by 185.1% during the fourth quarter. Meeder Asset Management Inc. now owns 34,237 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 22,227 shares in the last quarter. Teachers Advisors LLC grew its stake in Catalyst Pharmaceuticals by 12.0% during the third quarter. Teachers Advisors LLC now owns 218,143 shares of the biopharmaceutical company’s stock valued at $825,000 after acquiring an additional 23,321 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Catalyst Pharmaceuticals by 8.3% during the fourth quarter. Bank of New York Mellon Corp now owns 334,078 shares of the biopharmaceutical company’s stock valued at $641,000 after acquiring an additional 25,498 shares in the last quarter. Finally, Gables Capital Management Inc. grew its stake in Catalyst Pharmaceuticals by 7.3% during the fourth quarter. Gables Capital Management Inc. now owns 480,764 shares of the biopharmaceutical company’s stock valued at $923,000 after acquiring an additional 32,500 shares in the last quarter. 47.84% of the stock is owned by institutional investors.
CPRX has been the subject of several research analyst reports. BidaskClub raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 25th. ValuEngine lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $10.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Tuesday, March 19th. Finally, Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 13th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average price target of $6.55.
Catalyst Pharmaceuticals stock opened at $5.71 on Monday. The stock has a market capitalization of $587.01 million, a PE ratio of -17.30 and a beta of 2.43. Catalyst Pharmaceuticals Inc has a 12-month low of $1.85 and a 12-month high of $6.09.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.02). The firm had revenue of $0.50 million for the quarter. On average, research analysts expect that Catalyst Pharmaceuticals Inc will post -0.24 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Catalyst Pharmaceuticals Inc (CPRX) Shares Sold by Northern Trust Corp” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://transcriptdaily.com/2019/04/29/catalyst-pharmaceuticals-inc-cprx-shares-sold-by-northern-trust-corp.html.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Recommended Story: What is Net Asset Value (NAV)?
Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals Inc (NASDAQ:CPRX).
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.